S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
NASDAQ:OPTN

OptiNose - OPTN Stock Forecast, Price & News

$1.69
-0.04 (-2.31%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.58
$1.76
50-Day Range
$1.63
$1.90
52-Week Range
$1.55
$4.30
Volume
228,680 shs
Average Volume
207,361 shs
Market Capitalization
$188.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67

OptiNose MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
176.1% Upside
$4.67 Price Target
Short Interest
Bearish
4.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.10
Upright™ Environmental Score
News Sentiment
0.20mentions of OptiNose in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$90,443 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.38) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

321st out of 988 stocks

Pharmaceutical Preparations Industry

137th out of 482 stocks


OPTN stock logo

About OptiNose (NASDAQ:OPTN) Stock

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Receive OPTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

OPTN Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Optinose Announces CEO Transition and Business Update
Optinose Appoints Paul Spence as Chief Commercial Officer
Bucks County health care company expects to raise $50M
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates
See More Headlines
Receive OPTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

OPTN Company Calendar

Last Earnings
11/15/2021
Today
3/20/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPTN
Fax
N/A
Employees
189
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.67
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+176.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-74,830,000.00
Pretax Margin
-98.11%

Debt

Sales & Book Value

Annual Sales
$76.28 million
Book Value
($0.68) per share

Miscellaneous

Free Float
106,443,000
Market Cap
$188.96 million
Optionable
Not Optionable
Beta
-0.27

Key Executives

  • Ramy A. MahmoudRamy A. Mahmoud
    Chief Executive Officer & Director
  • John C. Messina
    SVP-Clinical Development & Medical Affairs
  • Michael C. Berkey
    Vice President-Technical Operations
  • Harry Sacks
    VP-Medical Affairs & Medical Officer
  • Anthony Kirck
    Chief Accounting Officer, VP & Controller













OPTN Stock - Frequently Asked Questions

Should I buy or sell OptiNose stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPTN shares.
View OPTN analyst ratings
or view top-rated stocks.

What is OptiNose's stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year price targets for OptiNose's shares. Their OPTN share price forecasts range from $4.00 to $5.00. On average, they expect the company's share price to reach $4.67 in the next twelve months. This suggests a possible upside of 176.1% from the stock's current price.
View analysts price targets for OPTN
or view top-rated stocks among Wall Street analysts.

How have OPTN shares performed in 2023?

OptiNose's stock was trading at $1.85 at the beginning of 2023. Since then, OPTN shares have decreased by 8.6% and is now trading at $1.69.
View the best growth stocks for 2023 here
.

When is OptiNose's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our OPTN earnings forecast
.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.05. The company earned $21.83 million during the quarter, compared to analyst estimates of $23.90 million. During the same period in the previous year, the business earned ($0.43) EPS.

What guidance has OptiNose issued on next quarter's earnings?

OptiNose issued an update on its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10.00 million-$10.00 million, compared to the consensus revenue estimate of $17.49 million.

What other stocks do shareholders of OptiNose own?
When did OptiNose IPO?

(OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Who are OptiNose's major shareholders?

OptiNose's stock is owned by many different retail and institutional investors. Top institutional investors include MVM Partners LLC (17.49%), Kingdon Capital Management L.L.C. (3.77%), Armistice Capital LLC (2.39%), Nantahala Capital Management LLC (1.74%), Rice Hall James & Associates LLC (0.97%) and Stonepine Capital Management LLC (0.61%). Insiders that own company stock include Joseph C Scodari, Keith A Goldan, Keith A Goldan, Michael F Marino III, Michael F Marino III, Michele Janis, Peter K Miller, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli.
View institutional ownership trends
.

How do I buy shares of OptiNose?

Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $1.69.

How much money does OptiNose make?

OptiNose (NASDAQ:OPTN) has a market capitalization of $188.96 million and generates $76.28 million in revenue each year. The company earns $-74,830,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does OptiNose have?

The company employs 189 workers across the globe.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The official website for the company is www.optinose.com. The company can be reached via phone at (267) 364-3500 or via email at investors@optinose.com.

This page (NASDAQ:OPTN) was last updated on 3/21/2023 by MarketBeat.com Staff